CAR T-cell Therapy Market (2025-2032)
The CAR T-cell Therapy Market is projected to reach $51.6 billion by 2032, at a CAGR of 43.3% from 2025 to 2032.
- Published
- Jan 2025
- Pages
- 230
- Format
- PDF + Excel
- Report ID
- MRHC - 104824
- Base year
- 2024
- 2032 · FORECAST
- $51.60B
- 2032
- $51.60B
- CAGR 2025–2032
- 43.3%
2024 baseline · 2025–2032 forecast at 43.3% CAGR · hover a bar for the value
Key highlights
In 2025, the Yescarta (axicabtagene ciloleucel) Segment is Expected to Dominate the CAR T-cell Therapy Market
In 2025, the CD Target Antigen Segment is Expected to Dominate the CAR T-cell Therapy Market
In 2025, the Lymphoma Segment is Expected to Dominate the CAR T-cell Therapy Market
Asia-Pacific: Fastest-growing Regional Market
Report summary
| Particulars | Details |
|---|---|
| Base Year | 2024 |
| Estimated Year | 2025 |
| Forecast Period | 2025–2032 |
| Market Size (2032) | USD 51.60 billion |
| CAGR (2025–2032) | 43.3% |
| Format | PDF, Excel & Cloud Portal · 230 pages |
| Segments Covered | By Drug Type: Abecma (idecabtagene vicleucel), Breyanzi (lisocabtagene maraleucel), Kymriah (tisagenlecleucel), Tecartus (brexucabtagene autoleucel), Yescarta (axicabtagene ciloleucel), Carvykti (ciltacabtagene autoleucel), Other Brands · By Target Antigen: CD, BCMA, HER2, Other Target Antigens · By Indication: Lymphoma, Acute Lymphoblastic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia, Other Indications · By Brand: Abecma, Breyanzi, Yescarta |
| Countries Covered | North America (Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific) |
| Key Companies | Novartis AG, Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A., Celyad Oncology SA, Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), OncoTherapy Science, Inc. |
Report overview
Segments covered: drug type, target antigen, indication, brand. Regions: North America, Europe, Asia-Pacific.
CAR T-cell therapy is a treatment modality where T cells are engineered. The engineered CAR T cell gets activated when it encounters an antigen on a cancer cell. Activated CAR T cells multiply, and cytokines and activated T-cells cause significant inflammation focused on the cancer cell resulting in cell death. Hence, this is a widely known therapy for cancer patients.
The growth of this market is driven by increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy may restrain the growth of this market. Additionally, a high scope in emerging economies, innovation in CAR T-cell therapies and manufacturing processes are creating opportunities for market growth. Moreover, the high treatment cost of therapy and the lack of skilled professionals are challenging factors for the market.
Report infographic
Market dynamics
1 factors across 1 forceIncreasing Cancer Prevalence Drives the Demand for CAR T-cell Therapy
According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with 10 million deaths globally in 2020. Nearly 70% of cancer deaths occur in low & middle-income countries. According to GLOBACAN, the global number of new cancer cases will reach 24,044,406 in 2032 from 19,292,789 in 2020. When compared among the regions, in North America, the new cancer cases will reach 3,070,906 in 2032 from 2,556,862 in 2020, while in Europe, the new cancer cases will reach 4,919,893 in 2032 from 4,395,052 in 2020. In Asia, the number of new cancer cases will reach 11,889,569 in 2032 from 9,386,454 in 2020.
Cancer incidence is increasing globally due to unhealthy diets, tobacco use, alcohol consumption, sedentary lifestyles, exposure to carcinogens, obesity, and pollution. This increasing cancer incidence is also estimated to put a tremendous economic strain on various economies. Early detection and treatment are critical to reducing mortality and improving the chances of survival. Various forms of cancer treatment are available, such as surgery, chemotherapy, and radiotherapy; however, therapeutic advancements to boost the efficacy of cancer treatment have led to the development of CAR T-cell therapy. CAR T-cell therapy is a precision medicine in which the engineered CAR T-cells bind to an antigen on the cancer cells and kill them. Due to its efficacy, the therapy is fast becoming a standard cancer treatment. Hence, the increasing cancer incidence drives the demand for CAR T-cell therapy.
Table of contents
11 chapters · 96 sections · 230 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Drug Type | Yescarta (axicabtagene ciloleucel) | — |
| By Target Antigen | CD Target Antigen | — |
| By Indication | Lymphoma | — |
By Drug Type
- The Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-Cell Therapy market.
- Yescarta (axicabtagene ciloleucel) treatment has been proven effective over other treatments.
- The drug has high efficacy in treating cancer in people with high-grade B-cell lymphoma (HGBL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL) that was not responding to earlier therapies.
- Hence, dominated the CAR T-cell therapy market.
By Target Antigen
- The CD target antigen segment is expected to account for the largest share of the CAR T-cell therapy market.
- CD is expressed throughout the B-cell developmental phase to terminal differentiation into plasma cells.
- As this antigen is very helpful for determining malignancies, most therapies, clinical trials, and research studies are based on CD target antigens.
By Indication
- The lymphoma segment is expected to account for the largest share of the CAR T-Cell Therapy market.
- Lymphoma is a group of blood cancers that develop from abnormal white blood cells or lymphocytes.
- Due to the increased cases of lymphoma, there was a rise in the adoption of CAR T-cell therapy for treating lymphoma, contributing to the large share of this segment.
Geographic analysis
Asia-Pacific
Fastest growthThe growth of this market is mainly driven by the large pool of patient population seeking cancer treatment, increasing prevalence of cancer, investments by the major players in the market, increasing government spending on healthcare, and growing disposable income of the population leading to improved access to cancer treatment. Asia-Pacific: Fastest-growing Regional Market
Competitive landscape
- Novartis AG · Switzerland
- Bristol-Myers Squibb Company (U.S.)
- Caribou Biosciences, Inc. (U.S.)
- Cartesian Therapeutics, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Cellectis S.A. · France
- Celyad Oncology SA · Belgium
- Gilead Sciences, Inc. (U.S.)
- Intellia Therapeutics, Inc. (U.S.)
- Merck & Co., Inc. (U.S.)
- Amgen Inc. (U.S.)
- Inovio Pharmaceuticals, Inc. (U.S.)
- OncoTherapy Science, Inc. · Japan
Frequently asked questions
The CAR T-cell therapy market encompasses treatments utilizing engineered T cells to target specific cancer cell antigens, leading to cell destruction and providing a precision medicine approach for oncology.
Cite this report
Meticulous Research. (2025). CAR T-cell Therapy Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MRHC - 104824). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/car-t-cell-therapy-market-5508